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Aims: Although endothelin (ET) is known to play pleiotropic roles in various pathological conditions, its relation
to autoimmune disease has not been elucidated. Here, we focused on interleukin (IL)-17, which is closely related
to the pathogenesis of multiple sclerosis, and investigated the effect of ET receptor blockers on the production of
IL-17 by T lymphocytes.
Mainmethods: Lymph node cells frommice at 8 days post-immunizationwithMOG35–55were stimulated in vitro
with MOG35–55 in the presence or absence of an ET receptor blocker (BQ123 for ETA or BQ788 for ETB). Naïve
T cells frommice were subjected to an in vitro model of Th17 differentiation, and ET-mediated IL-17 production
was investigated under the states of Th17 differentiation and activation.
Key ﬁndings: ELISA revealed thatMOG35–55-induced IL-17 productionwas signiﬁcantly inhibited by BQ123 but not
BQ788. Consistentwith the ELISA results for IL-17, the frequency of CD4+T cells producing IL-17 but not IFN-γwas
reduced by BQ123. Under the differentiating state from naïve T cells to Th17 cells, the spontaneous release of IL-17
from CD4+ T cells was increased, which was insensitive to BQ123, indicating that ET/ETA signaling did not affect
Th17 differentiation. After the time period of Th17 differentiation, however, the increase in IL-17 production by
restimulation of the cells with anti-CD3 plus anti-CD28 antibodies was signiﬁcantly inhibited by BQ123.
Signiﬁcance:Wedemonstrated that ET/ETA signaling plays a crucial role in IL-17 production by Th17. BQ123might
be expected to be a future therapeutic drug for multiple sclerosis.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
Endothelin-1 (ET-1), an extremely potent vasoconstrictor released
mainly by endothelial cells, exertsmany pleiotropic roles including effects
on the autoimmune system (Barton and Yanagisawa, 2008). Being the
only cells that promote differentiation of naïve T cells to effector T cells,
dendritic cells (DC) contribute importantly to the development of auto-
immune diseases (Banchereau et al., 2000). It has been shown that the
maturation of DC is associated with the production of large amounts of
ET-1, with concomitant upregulation of both ETA and ETB receptors
(ETAR and ETBR; Guruli et al., 2004). The incubation of immature DC
with an ETA receptor antagonist, BQ123, inhibited DC maturation and
interleukin (IL)-12 production, which promotes a type 1 T helper cell
(Th1) response.
Multiple sclerosis (MS) is a severe autoimmune demyelinating dis-
ease of the central nervous system (CNS). Though its clinical features
were ﬁrst depicted by Robert Carswell in 1838 (Compston, 1988), the
exact pathogenesis of and effective curative therapies for MS still re-
main to be established. An autoimmune rodent model of experimentaly and Molecular Pharmacology,
ana, Chuo-ku, Chiba 260-8670,
.
. This is an open access article underallergic encephalomyelitis (EAE) has proved useful for research on MS
(Lisak and Behan, 1975). EAE is initiated by immunization with myelin
peptide and complete Freund's adjuvant (CFA). Myelin-speciﬁc T cells
are activated by antigen presenting cells (APC) including DC in lymph
nodes, and cross the blood brain barrier (BBB) into the brain and spinal
cordwhere they are restimulated by APC to promotemyelin destruction
and trigger inﬂammation, astrogliosis and the production of chemotac-
tic cytokines (Rodgers and Miller, 2012). Recently, the view that Th1
cytokines were the main cause of EAE has been modiﬁed in light of
evidence showing a crucial participation of Th17 cytokines in its patho-
genic mechanisms (O'Garra et al., 1997; Kuwabara et al., 2009). IL-17,
which is mainly secreted by Th17, induces permeability of the BBB
and promotes recruitment of additional CD4+ T lymphocytes into the
CNS, leading to the development of EAE (Kebir et al., 2007).
Here, we have used an in vitro T cell differentiation/activation
system to investigate if ET-1, signaling through ET receptors (ETR),
might contribute to the pathogenesis of EAE.
Materials and methods
Animals
C57BL/6J mice were purchased from Clea Japan (Tokyo, Japan). All
animal procedures conformed to the Japanese regulations for animalthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Fig. 1. Upregulation of IL-17 inMOG35–55-speciﬁc LNCmediated by ET-1/ETR signaling. LNC isolated fromMOG35–55-immunizedmouse at 8 DPI were restimulated in vitro withMOG35–55 as
an antigen-speciﬁc response (gray columns) or anti-CD3/CD28 antibodies as an APC-free response (black columns) in the presence or absence of BQ123 or BQ788 for 72 h. As a negative con-
trol, LNCwere cultured for 72 hwithout restimulation (white columns). A)MOG35–55-induced IL-17 in LNC. Supernatantswere subjected to ELISA for IL-17. Data are shown asmean± S.E.M.
(n=3). *, P b 0.05 (ANOVA followed by Tukey test). B) Detection of Th17 cells by FACScan. Th17 cells were deﬁned as CD4+IL17+IFNγ− cells. The quantiﬁcation of Th17 cells was performed
with Flowjo software. Data are shown as mean ± S.E.M. (n = 3). *, P b 0.05 (ANOVA followed by Tukey test).
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the Japanese Association for Laboratory of Animal Science, and were
approved by the Animal Care and Use Committee of Chiba University.
MOG peptide
A synthetic peptide derived from myelin-oligodendrocyte-
glycoprotein sequence 35–55 (MEVGWYRSPFSRVVHLYRNGK,
MOG35–55) was synthesized by TORAY Research Center Inc. (Tokyo,
Japan).
Characterization of MOG35–55-speciﬁc LNC
WTmicewere immunized subcutaneously in fourﬂankswith 100 μg
MOG35–55 emulsiﬁed 1:1 in complete Freund's adjuvant (Difco, Franklin
Lakes, NJ, USA) supplemented with 500 μg Mycobacterium tuberculosis
H37Ra on day 0. A single cell suspension of lymph node cells (LNC)
was prepared from the axillary, inguinal, and cervical lymph nodes of
mice at 8 days post-immunization (DPI). Then, the cellswere stimulated
with 20 μg/mlMOG35–55 or 2 μg/ml anti-CD3plus anti-CD28 in LNCme-
dium (RPMI 1640 medium (Sigma, St. Louis, MO, USA) supplemented
with 10% FBS, 500 μM 2-mercaptoethanol, penicillin (100 units/ml),
and streptomycin (100 μg/ml)) at 37 °C in a humidiﬁed atmosphere
(5% CO2) in the presence or absence of BQ123 or BQ788 (1 × 10−5 M)
for 72h. As negative controls, LNCwere incubated in LNCmediumwith-
out any stimulator in the presence or absence of BQ123 or BQ788 for
72 h. The resulting supernatants and LNC were subjected to enzyme-
linked immunosorbent assay (ELISA) and intracellular cytokine staining
followed by ﬂow cytometric analysis, respectively. The ELISA was per-
formed according to the manufacturer's instructions for mouse IL-17A
ELISA MAX (Biolegend, San Diego, CA, USA). Cells were stained with
APC-conjugated CD4 antibody (Ab) (Biolegend). After ﬁxing and
permeabilizing (Fix/Perm buffer, Biolegend), the cells were further
stained with phycoerythrin-conjugated anti-IL-17 Ab and FITC-
conjugated anti-IFN-γ Ab (BD Biosciences). Analysis was performed
with a FACS Canto II ﬂow cytometer (BD Biosciences) and FlowJo
software (Tree Star Inc., Ashland, OR, USA).
In vitro model of Th17 differentiation
A single suspension of LNC was prepared from the axillary, inguinal,
and cervical lymph nodes of mice. Then, the puriﬁcation of CD4+ T cells
was performed with anti-CD4 magnetic microbeads (Miltenyi Biotech,
Gladbach, Germany) in combination with MACS columns. CD4+ T cells
were incubated in LNC medium containing anti-CD3 plus anti-CD28 Abs
(1 μg/ml each) and Th17-polarizing agents (30 ng/ml IL-6, 1 ng/ml TGF-β, 10 μg/ml anti-mouse IL-4 and 10 μg/ml anti-mouse IFN-γ) for 72 h as
a Th17-polarizing period. As a negative control, 72-h incubation
was conducted without the Th17-polarizing agents. Then, the cells
were restimulated with anti-CD3 plus anti-CD28 Abs for another 6
h as an activation period of Th17 cells. To evaluate the effect of
BQ123 or BQ788 (1 × 10−5 M), each agent was added to the medium
for the Th17-polarizing period or activation period of Th17 cells. The
supernatants and cells under each condition were subjected to ELISA
and RNA preparation, respectively.
RT-PCR for RORγt
In order to assess Th17 cell differentiation, we carried out assays to
quantify mRNA expression of the orphan nuclear receptor RORγt, a
transcription factor which directs this process. Single strand cDNA was
synthesized from prepared total RNA (1 μg), with MMLV reverse tran-
scriptase (Invitrogen, Carlsbad, CA, USA) using an oligo (dT) primer
(Invitrogen) in a total volume of 20 μl. The resultant cDNA sample
(1 μl) was subjected to PCR for ampliﬁcation of mouse RORγt and
mouse peptidylprolyl isomerase A (PPIA as an internal control) using
speciﬁc primers (for RORγt, sense primer, 5′-CCGCTGAGAGGGCTTC
AC-3′; antisense primer, 5′-TGCAGGAGTAGGCCACATTACA-3′, for PPIA,
sense primer, 5′-AGGTCCATCTACGGAGAG-3′; antisense primer, 5′-
TCAGTCTTGGCAGTGCAG-3′). The settings of the thermal cycler were
22 cycles of 15 s at 98 °C, 30 s at 60 °C, 45 s at 68 °C, and 7 min at
68 °C for RORγt and 27 cycles of 15 s at 98 °C, 30 s at 55 °C, 45 s at
68 °C for PPIA. The ampliﬁed products were separated in 1.2% agarose
gel and visualized with ethidium bromide staining under UV radiation.
The speciﬁc ampliﬁcation of the expected size (mouse RORγt, 230 bp;
PPIA, 134 bp) was observed.
Statistics
Data are expressed as mean ± S.E.M. Statistical analysis was
conducted using Graphpad Prism Version 6 (GraphPad Software
Inc., San Diego, CA, USA). Statistical signiﬁcance was determined by
analysis of variance (ANOVA) followed by Tukey test, and P values
b 0.05 were considered signiﬁcant.
Results and discussion
It has been demonstrated that plasma ET-1 level is elevated in pa-
tients withMS, suggesting the possible involvement of ET-1 in the path-
ogenesis of MS (Haufschild et al., 2001). Very recently, a correlation
between ET-1 and MS development associated with a decrease in cere-
bral blood ﬂow (CBF) has been reported (D'haeseleer et al., 2013). In
Fig. 2. Effect of BQ123 on in vitro Th17 cell differentiation. CD4+ naïve T cells were induced to differentiate to Th17 in vitro by incubationwith anti-CD3/CD28Abs concomitantlywith (PC)
or without Th17-polarizing agents (NC) for 72 h (Th17-polarizing period), followed by another 6-h restimulation with anti-CD3/CD28Abs (activation period of Th17); positive control
(PC). As a negative control for activation period of Th17, CD4+ naïve T cells were incubated with anti-CD3/CD28 Abs during Th17-polarizing period, followed by incubated with vehicle
during activation period. To evaluate the effects of BQ123 on the Th17-polarizing period and activation period of Th17, BQ123was added to the culture medium of positive control during
eachperiod. A) BQ123 affected Th17-derived IL17 production during the activation period of Th17 but not the Th17-polarizing period. Data are shown asmean± S.E.M. (n=3). *, P b 0.05
(ANOVA followed by Tukey test). B) The induction of RORγt mRNA during Th17-polarizing periodwas insensitive to BQ123. As a negative control (NC), mRNA from the CD4+ naïve T cells
was used. As an internal control, RT-PCR was performed for peptidylprolyl isomerase A (PPIA).
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from reactive astrocytes in MS plaques was shown to lead to a reduction
of CBF in MS patients. Likewise, administration of bosentan (a nonselec-
tive ET-1 antagonist) to patients with MS can restore CBF to a normal
level. These ﬁndings suggest that ET-1 may be one of the therapeutic
targets for MS.
Considering the immune system, however, there is no report about
the contribution of ET-1 to the pathogenesis of MS. Th17 cell-derived
IL-17 is known to be a major mediator in EAE and MS (Komiyama
et al., 2006;Wang et al., 2011). In the present study, we therefore inves-
tigated whether ET-1 regulates the function of the IL-17-producing
T cell subset.
To evaluate whether ET-1/ETR signaling participates in IL-17 pro-
duction by encephalitogenic antigen-speciﬁc effector T cells, LNC from
MOG35–55-immunized mice were subjected to in vitro restimulation in
the presence or absence of an ETR antagonist. As shown in Fig. 1A, re-
stimulation of LNC with MOG35–55 induced IL-17 production, which
was signiﬁcantly inhibited by BQ123 but not BQ788. This ﬁnding sug-
gests that ET-1/ETAR signaling can regulate T cell-derived IL-17 produc-
tion closely related to the pathogenesis of EAE. This notion was
supported by ﬂow cytometric analysis of intracellular IL-17 in CD4+
T cells. Consistent with the ELISA results for IL-17, the frequency of
CD4+ T cells producing IL-17 in LNC treated with BQ123 was signiﬁ-
cantly lower than that in control LNC in the case of stimulation with
MOG35–55 (Fig. 1B). On the other hand, the stimulation of LNC with
anti-CD3/CD28 Abs, mimicking antigen contact via APC also upregulat-
ed both IL-17 production and the frequency of CD4+ T cells producing
IL-17, which were sensitive to BQ123 treatment (Fig. 1A & B). This fact
indicates that ET-1/ETAR signaling can regulate CD4+ T cell-derived
IL-17 production even in an APC-free system. Although the existence
of the ET-1/ETR system inmacrophages has been shown, ET-1/ETAR sig-
naling seems not to affect the antigen-presenting capacity of macro-
phages in the activation of effector T cells (Ruetten and Thiemermann,
1997). Taken together, these results suggest the possibility that ET-1/
ETAR signaling affects Th17 differentiation or the IL-17-producing activ-
ity of Th17 cells.
To assess these possibilities, isolated naïve T cell was subjected to a
Th17-polarizing condition. Prior to examination, the mRNA expression
of preproET-1 and ETAR in naïve T cells was conﬁrmed (data not
shown). As shown in Fig. 2A, IL-17 production was induced during the
Th17-polarizing period even in the presence of BQ123, suggesting that
ET-1/ETAR signaling is not involved in Th17 differentiation. This notion
was strongly supported by the ﬁnding that the Th17-polarizing agents-
inducedmRNA level of the orphan nuclear receptor RORγt was not sup-
pressed by BQ123 (Fig. 2B). RORγt is a transcription factor directing thedifferentiation of IL-17-producing inﬂammatory T cells, and is used as a
marker of Th17 differentiation (Ivanov et al., 2006). On the other hand,
restimulation of Th17-polarized CD4+ T cells with anti-CD3/CD28 Abs
markedly induced IL-17 production, which was signiﬁcantly inhibited
by BQ123. These results suggest that ET-1/ETAR signaling regulates
IL-17 production by Th17 cells in an autocrine/paracrine manner.
Currently, the ﬁrst-line treatments for control of MS are glatiramer
acetate, interferon (IFN) β-1a, IFNβ-1b and the new orally active
sphingosine-1-phosphate receptor modulator ﬁngolimod, and some
monoclonal antibodies are in late stages of development (Jeffery,
2013). Likewise, G-protein-coupled receptors (GPCRs) were recently
recognized as therapeutic targets for MS. In addition to chemokine re-
ceptor modulators under clinical investigation for MS, GPCRs for bioac-
tive peptides are also expected to become new therapeutic targets for
this disease in the near future (Du and Xie, 2012). Both the previous
report by D'haeseleer et al. (2013) and our present study place ETRs
(particularly the ETAR) in the list of GPCRs that are potentially relevant
therapeutic targets for MS.
Conclusion
The present study indicated the presence of an ET-1/ETAR signal-
ing loop in IL-17-producing T lymphocytes. Although further study is
needed to evaluate the therapeutic effect of ETR antagonists using an
in vivo MS model, our study might provide a new insight into MS
treatment.
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